Valuation: Sunshine Heart Inc

Market Cap 2.29M 2.06M 1.9M 1.72M 3.22M 218M 3.26M 22.75M 9.06M 114M 8.61M 8.43M 363M P/E 2024 *
-
P/E 2025 -
Enterprise Value 1.54M 1.38M 1.27M 1.15M 2.16M 146M 2.18M 15.24M 6.07M 76.59M 5.77M 5.64M 243M EV / Sales 2024
-0.06x
EV / Sales 2025 0.26x
Free-Float
11%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-29
Director of Finance/CFO 48 2026-02-01
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 76 2011-08-02
Chairman 77 2012-09-30
Director/Board Member 63 2023-10-31
Change 5-day change 1-year change 3-year change Capi.($)
-7.46%-13.61% - - 2.19M
+1.61%+1.46%+26.28%+63.22% 256B
+0.89%+0.09%+7.92%+24.58% 163B
-0.38%+3.75%-18.56%+71.51% 155B
-5.84%-4.67%-57.98%-14.32% 65.3B
+1.06%+3.82%+11.67%+48.73% 52.35B
+1.72%+2.11%-12.83%-7.13% 51.93B
+1.39%-0.85%+9.09%+67.70% 50.75B
+2.25%+2.10%+24.43%+76.59% 50.04B
+1.78%+4.24%+37.85%+94.84% 46.03B
Average -0.30%+1.34%+3.09%+47.30% 98.94B
Weighted average by Cap. +0.59%+1.38%+5.32%+49.58%

Financials

2024 2025
Net sales 8.74M 7.84M 7.25M 6.57M 12.27M 832M 12.42M 86.68M 34.53M 436M 32.8M 32.11M 1.38B 8.27M 7.42M 6.86M 6.21M 11.61M 788M 11.75M 82.02M 32.67M 412M 31.03M 30.38M 1.31B
Net income -11.16M -10.02M -9.26M -8.39M -15.67M -1.06B -15.86M -111M -44.11M -556M -41.9M -41.01M -1.77B -17.52M -15.72M -14.53M -13.16M -24.59M -1.67B -24.89M -174M -69.21M -873M -65.75M -64.36M -2.77B
Net Debt -4.55M -4.08M -3.77M -3.42M -6.39M -433M -6.46M -45.13M -17.97M -227M -17.07M -16.71M -720M -757K -679K -628K -569K -1.06M -72.1M -1.08M -7.51M -2.99M -37.73M -2.84M -2.78M -120M
Logo Sunshine Heart Inc
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Employees
-